Inhibikase Therapeutics (NYSE:IKT – Free Report) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 […]